Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals accelerates growth with Kashiv BioSciences acquisition, strong Q1 results, and positive Phase 4 data for Parkinson’s drug CREXONT.

Amneal Pharmaceuticals Inc has made strategic financial moves to strengthen its balance sheet and support future growth, including a proposed refinancing of its credit agreement and a 3% revenue growth in Q2.

Amneal Pharmaceuticals Inc. reports strong Q1 2025 performance, with 5% revenue growth and 50% EPS increase, driven by strategic initiatives and focus on high-growth therapeutic areas.